Evolution of Patients with Pulmonary Arterial Hypertension Starting Macitentan After the Discontinuation of Other Endothelin-Receptor Antagonists: Results of a Retrospective Study
| Autor: | Juan Ortiz de Saracho, Pedro Bedate Díaz, José Manuel Cifrián Martínez, Sergio Cadenas-Menéndez, Armando Oterino Manzanas, Vicente Roig Figueroa, Pilar Alonso Lecue, Pablo Álvarez Vega |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Endothelin Receptor Antagonists
Male medicine.medical_specialty Ambrisentan Walk Test 030204 cardiovascular system & hematology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Pharmacotherapy Internal medicine Natriuretic Peptide Brain Medicine Humans Pharmacology (medical) 030212 general & internal medicine Macitentan Aged Retrospective Studies Pulmonary Arterial Hypertension Sulfonamides business.industry Retrospective cohort study General Medicine Brain natriuretic peptide Bosentan Peptide Fragments Discontinuation Pyrimidines Treatment Outcome chemistry Echocardiography Spain Concomitant Female Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | American journal of cardiovascular drugs : drugs, devices, and other interventions. 20(5) |
| ISSN: | 1179-187X |
| Popis: | Macitentan is the latest endothelin-receptor antagonist (ERA) approved for the treatment of pulmonary arterial hypertension (PAH), presenting enhanced properties over previous ERAs. We describe the clinical and echocardiographic evolution of patients with PAH who started macitentan after discontinuing bosentan/ambrisentan. This was a retrospective series of patients with different etiologies who started macitentan after the suspension of other ERAs under routine clinical practice at five Spanish hospitals. World Health Organization functional class (WHO-FC), 6-min walk distance (6MWD), levels of N-terminal prohormone of brain natriuretic peptide (NT-proBNP), and cardiac imaging data were collected and described at baseline (before macitentan initiation) and after 3, 6, and 12 months, when available. In total, 12 patients (ten women; mean age 65.63 ± 13.27 years) were observed. At baseline, most patients were receiving concomitant PAH medications, and five patients were classed as WHO-FC III. After 3 months of macitentan treatment, WHO-FC had improved in four patients, 6MWD increased in eight patients, and NT-proBNP levels and right atrial area were lowered in seven and eight patients, respectively. Similar results were observed after 6 and 12 months. Macitentan was well-tolerated, with no PAH hospitalizations, septostomies, transplants, or deaths registered. Our results suggest that switching to macitentan in patients with PAH who discontinued bosentan/ambrisentan was well-tolerated and effective. Further studies are needed to confirm these observations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink